Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fotemustine IV vs IA in Liver Metastases from Uveal Melanoma
NCT00110123Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2005
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of fotemustine in Uveal melanoma (UM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Jan 2005; status: terminated.
02
Drugs
fotemustine
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00110123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110123.